Day: August 29, 2022

KINFAST to evaluate ability of KIN001 to reduce severity and duration of symptoms in ambulatory COVID-19 patients Interim data from ongoing Phase 2 KINETIC trial in hospitalized Covid-19 patients expected in late Q3 2022Basel, Switzerland, 29 August 2022 — Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus”), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases today announced that the first patient has been dosed in the Phase 2 KINFAST trial, a multicenter placebo-controlled trial evaluating KIN001 in mild or moderate COVID-19 patients in an outpatient setting. The trial will enroll patients at clinical trial sites in Switzerland and Germany. The KINFAST trial is partly supported by a non-diluting grant from the Programme for COVID-19 medicines of the...

OSLO, Norway (29 August 2022) – TGS, a global provider of energy data and intelligence, today announced Swanson 3D, a new onshore multi-client 3D seismic survey within the Montney Basin of Northeast British Columbia, Canada. The Swanson 3D project will add over 100 square kilometers of high-quality seismic data, complimenting the extensive 3D seismic coverage within the core area of the Montney Basin. Phase IV of TGS’ low-impact source testing will be applied throughout the project, reinforcing our commitment to dramatically lowering environmental footprints throughout seismic acquisition projects. Through cooperation with the area’s Stakeholders and several First Nation Communities, the pre-planning for Swanson 3D is well underway. Fuel emissions recording, reduced line widths, no-cut areas and low-impact source methods will be...

Saint-Herblain (France), August 29, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported further positive Phase 3 results for its inactivated, adjuvanted COVID-19 vaccine VLA2001. Additional readouts from the Company’s pivotal VLA2001-301 “Cov-Compare” trial showed persistent immunogenicity and first positive heterologous booster results following primary vaccination with ChAdOx1-S (AstraZeneca). The Company previously reported immunogenicity data at Day 43 post primary vaccination1 and has now evaluated immunogenicity in VLA2001-301 trial participants approximately two months following primary immunization (“Day 71”), as part of the prespecified analysis of secondary endpoints. At Day 71, neutralizing antibody titers induced by VLA2001 were non-inferior to ChAdOx1-S: VLA2001 GMT was 444.0...

Pixium Vision announces participation in upcoming scientific conferences in September 2022 Paris, France, August 29, 2022 – 07:00 CET – Pixium Vision SA (Euronext Growth Paris – FR0011950641; Mnemo: ALPIX), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, announces today that senior management will participate in the following scientific conferences during September 2022:22nd EURETINA Congress, September 1 – 4, Hamburg & VirtualLloyd Diamond, Chief Executive Officer, Ralf Hornig, PhD, Director of Clinical Affairs, and Professor Frank G. Holz, Scientific Advisor, to attend in-person. Information on registering for the conference is available here.Eyecelerator @ AAO 2022, September 29, ChicagoRalf Hornig, PhD, Director...

 Papendrecht and Monaco, 29 August 2022, 7.15 CET This joint press release by Koninklijke Boskalis Westminster N.V (‘‘Boskalis’’) and HAL Holding N.V. (“HAL Holding”) is issued pursuant to the provisions of article 4, paragraph 3, article 13, paragraphs 1 and 2 and article 15, paragraph 4 of the Dutch Decree on Public Takeover Bids (Besluit openbare biedingen Wft) (the “Decree”) in connection with the public offer (the “Offer”) by HAL Bidco B.V. (the “Offeror”), a direct wholly-owned subsidiary of HAL Investments B.V., for all the issued and outstanding ordinary shares in the capital of Boskalis. This press release does not constitute an offer, or any solicitation of any offer, to buy or subscribe for any securities. An offer is made only by means of the offer memorandum dated 23 June 2022 (the “Offer Memorandum”). This press release is...